<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: certain risk factors", fill: "#96c"},
{source: "1: certain risk factors", target: "1: could affect", fill: "#96c"},
{source: "1: could affect", target: "1: Companys ", fill: "#96c"},
{source: "1: Companys ", target: "1: financial condition", fill: "#96c"},
{source: "1: financial condition", target: "1: operations", fill: "#96c"},
{source: "1: certain risk factors", target: "6: businesses", fill: "#0000cd"},
{source: "6: businesses", target: "6: highly competitive", fill: "#0000cd"},
{source: "6: highly competitive", target: "6: compete successfully", fill: "#0000cd"},
{source: "6: compete successfully", target: "6: Companys ", fill: "#0000cd"},
{source: "6: Companys ", target: "6: operations may", fill: "#0000cd"},
{source: "6: operations may", target: "6: negatively affected", fill: "#0000cd"},
{source: "6: businesses", target: "7: The Company ", fill: "#ffefd5"},
{source: "7: The Company ", target: "7: highly competitive global environment", fill: "#ffefd5"},
{source: "7: highly competitive global environment", target: "7: businesses with", fill: "#ffefd5"},
{source: "7: businesses with", target: "7: broad line manufacturers", fill: "#ffefd5"},
{source: "7: broad line manufacturers", target: "7: smaller competitors specializing", fill: "#ffefd5"},
{source: "7: smaller competitors specializing", target: "7: particular products primarily on", fill: "#ffefd5"},
{source: "7: particular products primarily on", target: "7: product quality price warranty delivery service", fill: "#ffefd5"},
{source: "7: The Company ", target: "12: success depends on", fill: "#ffcba4"},
{source: "12: success depends on", target: "12: design manufacture", fill: "#ffcba4"},
{source: "12: design manufacture", target: "12: market acceptance", fill: "#ffcba4"},
{source: "12: market acceptance", target: "12: new products with higher", fill: "#ffcba4"},
{source: "12: new products with higher", target: "12: functionality", fill: "#ffcba4"},
{source: "12: functionality", target: "12: lower costs", fill: "#ffcba4"},
{source: "12: success depends on", target: "14: The Company ", fill: "#701c1c"},
{source: "14: The Company ", target: "14: product development", fill: "#701c1c"},
{source: "14: product development", target: "14: improvement", fill: "#701c1c"},
{source: "14: improvement", target: "14: must continue", fill: "#701c1c"},
{source: "14: must continue", target: "14: improve innovative products", fill: "#701c1c"},
{source: "14: improve innovative products", target: "14: effectively distribute", fill: "#701c1c"},
{source: "14: effectively distribute", target: "14: market acceptance", fill: "#701c1c"},
{source: "14: market acceptance", target: "14: compete successfully with", fill: "#701c1c"},
{source: "14: compete successfully with", target: "14: competitors", fill: "#701c1c"},
{source: "14: The Company ", target: "27: Decreased ", fill: "#9457eb"},
{source: "27: Decreased ", target: "27: availability", fill: "#9457eb"},
{source: "27: availability", target: "27: increased costs", fill: "#9457eb"},
{source: "27: increased costs", target: "27: raw materials", fill: "#9457eb"},
{source: "27: raw materials", target: "27: energy costs", fill: "#9457eb"},
{source: "27: energy costs", target: "27: could increase", fill: "#9457eb"},
{source: "27: could increase", target: "27: Companys ", fill: "#9457eb"},
{source: "27: Decreased ", target: "39: problems could", fill: "#882d17"},
{source: "39: problems could", target: "39: disruption delay", fill: "#882d17"},
{source: "39: disruption delay", target: "39: adversely", fill: "#882d17"},
{source: "39: adversely", target: "39: productivity", fill: "#882d17"},
{source: "39: productivity", target: "39: profitability", fill: "#882d17"},
{source: "39: profitability", target: "39: particular manufacturing facility", fill: "#882d17"},
{source: "39: particular manufacturing facility", target: "39: Companys ", fill: "#882d17"},
{source: "39: Companys ", target: "39: operations as", fill: "#882d17"},
{source: "39: operations as", target: "39: difficulties", fill: "#882d17"},
{source: "39: problems could", target: "47: compliance with multiple", fill: "#674846"},
{source: "47: compliance with multiple", target: "47: potentially conflicting international laws", fill: "#674846"},
{source: "47: potentially conflicting international laws", target: "47: regulations", fill: "#674846"},
{source: "47: regulations", target: "47: export limitations", fill: "#674846"},
{source: "47: export limitations", target: "47: exchange controls", fill: "#674846"},
{source: "47: compliance with multiple", target: "57: regulatory requirements", fill: "#0f0"},
{source: "57: regulatory requirements", target: "57: regulatory clearance", fill: "#0f0"},
{source: "57: regulatory clearance", target: "57: certain products", fill: "#0f0"},
{source: "57: certain products", target: "57: operations", fill: "#0f0"},
{source: "57: regulatory requirements", target: "61: offer no assurance", fill: "#de3163"},
{source: "61: offer no assurance", target: "61: such approval", fill: "#de3163"},
{source: "61: such approval", target: "61: clearance will", fill: "#de3163"},
{source: "61: clearance will", target: "61: applicable regulatory agency", fill: "#de3163"},
{source: "61: offer no assurance", target: "62: Additionally the Company ", fill: "#f0fff0"},
{source: "62: Additionally the Company ", target: "62: approvals approval", fill: "#f0fff0"},
{source: "62: approvals approval", target: "62: supplements", fill: "#f0fff0"},
{source: "62: supplements", target: "62: clearances", fill: "#f0fff0"},
{source: "62: clearances", target: "62: market modifications", fill: "#f0fff0"},
{source: "62: market modifications", target: "62: existing products", fill: "#f0fff0"},
{source: "62: existing products", target: "62: market existing products", fill: "#f0fff0"},
{source: "62: Additionally the Company ", target: "63: Regulatory ", fill: "#734f96"},
{source: "63: Regulatory ", target: "63: agencies may", fill: "#734f96"},
{source: "63: agencies may", target: "63: manufacturers", fill: "#734f96"},
{source: "63: manufacturers", target: "63: document determination", fill: "#734f96"},
{source: "63: document determination", target: "63: modification", fill: "#734f96"},
{source: "63: modification", target: "63: approval supplement", fill: "#734f96"},
{source: "63: approval supplement", target: "63: clearance however", fill: "#734f96"},
{source: "63: clearance however", target: "63: regulatory agencies may review", fill: "#734f96"},
{source: "63: regulatory agencies may review", target: "63: disagree with", fill: "#734f96"},
{source: "63: Regulatory ", target: "67: additional clinical", fill: "#eb4c42"},
{source: "67: additional clinical", target: "67: preclinical data", fill: "#eb4c42"},
{source: "67: preclinical data", target: "67: approved by", fill: "#eb4c42"},
{source: "67: approved by", target: "67: regulatory", fill: "#eb4c42"},
{source: "67: additional clinical", target: "92: The Company ", fill: "#507d2a"},
{source: "92: The Company ", target: "92: lawsuits regulatory", fill: "#507d2a"},
{source: "92: lawsuits regulatory", target: "92: proceedings", fill: "#507d2a"},
{source: "92: proceedings", target: "92: investigations", fill: "#507d2a"},
{source: "92: investigations", target: "92: debarment", fill: "#507d2a"},
{source: "92: debarment", target: "92: potential risks", fill: "#507d2a"},
{source: "92: potential risks", target: "92: liabilities", fill: "#507d2a"},
{source: "92: The Company ", target: "START_HERE", fill: "#507d2a"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Home Improvement Retail</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Property and Casualty Insurance</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Company">Company</a></td>
      <td>A company, abbreviated as co., is a legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective. Company members share a common purpose and unite to achieve specific, declared goals.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Holding_company">Holding company</a></td>
      <td>A holding company is a company whose primary business is holding a controlling interest in the securities of other companies. A holding company usually does not produce goods or services itself.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_largest_companies_in_the_United_States_by_revenue">List of largest companies in the United States by revenue</a></td>
      <td>This list comprises the largest companies in the United States by revenue as of 2022, according to the Fortune 500 tally of companies. Retail corporation Walmart has been the largest company in the US by revenue since 2014.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Víctor_Gay_Zaragoza">Víctor Gay Zaragoza</a></td>
      <td>Víctor Gay Zaragoza (born 19 June 1982 in Barcelona, Spain) is a writer, storyteller, trainer and consultant on storytelling. He is author of the essays "Filosofía Rebelde" (Rebel Philosophy), "50 libros que cambiarán tu vida" (50 books that will change your life) and the historical novel "El defensor" (The defender).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_RTO_districts_in_Kerala">List of RTO districts in Kerala</a></td>
      <td>\n== Regional Transport Offices ==\n\n\n== Sub Regional Transport Offices ==\n\n\n== Future Sub Regional Transport Offices ==\nGovernment of Kerala has repeatedly intimated multiple legislative members that there are no plans to setup any new RTOs/SRTOs in Kerala unless the financial condition of Kerala improves.\n\n\n== References ==\n\nOfficial list of Regional Transport Offices\nOfficial list of Sub Regional Transport Offices\n\n\n== External links ==\nhttps://www.mvd.kerala.gov.in (Link to Kerala Motor Vehicles Department.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Walt_Disney_Company">The Walt Disney Company</a></td>
      <td>The Walt Disney Company, commonly known as Disney (), is an American multinational mass media and entertainment conglomerate headquartered at the Walt Disney Studios complex in Burbank, California.\nDisney was originally founded on October 16, 1923, by brothers Walt and Roy O. Disney as the Disney Brothers Cartoon Studio; it also operated under the names the Walt Disney Studio and Walt Disney Productions before changing its name to the Walt Disney Company in 1986.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_female_fitness_and_figure_competitors">List of female fitness and figure competitors</a></td>
      <td>This is a list of female fitness and figure competitors.\n\n\n== A ==\nJelena Abbou\n\n\n== B ==\nLauren Beckham\nAlexandra Béres\nSharon Bruneau\n\n\n== C ==\nNatalie Montgomery-Carroll\nJen Cassetty\nKim Chizevsky\nSusie Curry\n\n\n== D ==\nDebbie Dobbins\nNicole Duncan\n\n\n== E ==\nJamie Eason\nAlexis Ellis\n\n\n== F ==\nAmy Fadhli\nJaime Franklin\n\n\n== G ==\nAdela García \nConnie Garner\nElaine Goodlad\nTracey Greenwood\nOksana Grishina\n\n\n== H ==\nMallory Haldeman\nVanda Hădărean\nJen Hendershott\nSoleivi Hernandez\nApril Hunter\n\n\n== I ==\n\n\n== J ==\nTsianina Joelson\n\n\n== K ==\nAdria Montgomery-Klein\nAshley Kaltwasser\n\n\n== L ==\nLauren Lillo\nMary Elizabeth Lado\nTammie Leady\nJennifer Nicole Lee\nAmber Littlejohn\nJulie Lohre\nJenny Lynn\n\n\n== M ==\nTimea Majorová\nLinda Maxwell\nDavana Medina\nJodi Leigh Miller\nChisato Mishima\n\n\n== N ==\nKim Nielsen\n\n\n== O ==\n\n\n== P ==\nVicky Pratt\nElena Panova\nChristine Pomponio-Pate\nCathy Priest\n\n\n== Q ==\n\n\n== R ==\nMaite Richert\nCharlene Rink\nKelly Ryan\n\n\n== S ==\nErin Stern\nCarol Semple-Marzetta\nKrisztina Sereny\nTrish Stratus (Patricia Anne Stratigias)\n\n\n== T ==\nKristi Tauti\nJennifer Thomas\n\n\n== U ==\n\n\n== V ==\nLisa Marie Varon\n\n\n== W ==\nLatisha Wilder\nTorrie Wilson\nLyen Wong\nJenny Worth\nNicole Wilkins\n\n\n== Y ==\n\n\n== Z ==\nMarietta Žigalová\nMalika Zitouni\n\n\n== See also ==\nList of female bodybuilders\n\n\n== References ==\nThere has been a rise in the number of women wanting to compete as fitness models.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Not_Available">Not Available</a></td>
      <td>Not Available is the second studio album (released as the fourth) by the Residents, recorded in 1974. The album was allegedly meant to only be released once its creators completely forgot about its existence (adhering to their "Theory of Obscurity," in which an artist's purest work is created without an audience) - however, due to ongoing delays in the release of Eskimo, Not Available was released to supply the demand for new Residents material, given their unexpected critical and commercial success following the release of the Duck Stab EP.\n\n\n== History ==\nIt is said that the lyrics and themes of Not Available arose from personal tensions within the group, and that the project began as a private psychodrama before being adapted into a possible operetta.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/High-availability_cluster">High-availability cluster</a></td>
      <td>High-availability clusters (also known as HA clusters, fail-over clusters) are groups of computers that support server applications that can be reliably utilized with a minimum amount of down-time.  They operate by using high availability software to harness redundant computers in groups or clusters that provide continued service when system components fail.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Learning_difficulties">Learning difficulties</a></td>
      <td>Learning disability, learning disorder, or learning difficulty (British English) is a condition in the brain that causes difficulties comprehending or processing information and can be caused by several different factors.  Given the "difficulty learning in a typical manner", this does not exclude the ability to learn in a different manner.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Desirable_difficulty">Desirable difficulty</a></td>
      <td>A desirable difficulty is a learning task that requires a considerable but desirable amount of effort, thereby improving long-term performance. It is also described as a learning level achieved through a sequence of learning tasks and feedback that lead to enhanced learning and transfer.As the name suggests, desirable difficulties should be highly desirable and increasingly challenging.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Strengths_and_Difficulties_Questionnaire">Strengths and Difficulties Questionnaire</a></td>
      <td>The Strengths and Difficulties Questionnaire (SDQ) is a self-report inventory behavioral screening questionnaire for children and adolescents ages 2 through 17 years old, developed by United Kingdom child psychiatrist Robert N. Goodman. The SDQ has been translated into more than 80 languages, including Spanish, Chinese, Russian, and Portuguese.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_affairs">Regulatory affairs</a></td>
      <td>Regulatory affairs (RA), also called government affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, cosmetics, agrochemicals (plant protection products and fertilizers), energy, banking, telecom etc.  Regulatory affairs also has a very specific meaning within the healthcare industries (pharmaceuticals, medical devices, biologics and functional foods).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clearance_rate">Clearance rate</a></td>
      <td>In criminal justice, clearance rate is calculated by dividing the number of crimes that are "cleared" (a charge being laid) by the total number of crimes recorded. Clearance rates are used by various groups as a measure of crimes solved by the police.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lowland_Clearances">Lowland Clearances</a></td>
      <td>The Lowland Clearances were one of the results of the Scottish Agricultural Revolution, which changed the traditional system of agriculture which had existed in Lowland Scotland in the seventeenth century. Thousands of cottars and tenant farmers from the southern counties (Lowlands) of Scotland migrated from farms and small holdings they had occupied to the new industrial centres of Glasgow, Edinburgh and northern England  or abroad, or remaining upon land though adapting to the Scottish Agricultural Revolution.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/DMG_Clearances">DMG Clearances</a></td>
      <td>DMG Clearances, Inc is a company based in Hockessin, Delaware, USA, which handles music clearances and licensing for the entertainment industry. DMG Clearances was founded in 1996 by Deborah Mannis-Gardner.The company clears musical compositions for use in films, video games, sampling and Broadway Theater.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sequence">Regulatory sequence</a></td>
      <td>A regulatory sequence is a segment of a nucleic acid molecule which is capable of increasing or decreasing the expression of specific genes within an organism. Regulation of gene expression is an essential feature of all living organisms and viruses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cis-regulatory_element">Cis-regulatory element</a></td>
      <td>Cis-regulatory elements (CREs) or Cis-regulatory modules (CRMs) are regions of non-coding DNA which regulate the transcription of neighboring genes. CREs are vital components of genetic regulatory networks, which in turn control morphogenesis, the development of anatomy, and other aspects of embryonic development, studied in evolutionary developmental biology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Conference_proceeding">Conference proceeding</a></td>
      <td>In academia and librarianship, conference proceedings is a collection of academic papers published in the context of an academic conference or workshop. Conference proceedings typically contain the contributions made by researchers at the conference.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Removal_proceedings">Removal proceedings</a></td>
      <td>Removal proceedings are administrative proceedings to determine an individual's removability under United States immigration law.  Removal proceedings are typically conducted in Immigration Court (the Executive Office for Immigration Review) by an immigration judge (IJ).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proceedings_of_the_Royal_Society">Proceedings of the Royal Society</a></td>
      <td>Proceedings of the Royal Society is the parent title of two scientific journals published by the Royal Society. Originally a single journal, it was split into two separate journals in 1905:\n\nPart A: which publishes research related to mathematical, physical, and engineering sciences (including computer science)\nPart B: which publishes research related to biologyThe two journals are the Royal Society's main research journals.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stay_of_proceedings">Stay of proceedings</a></td>
      <td>A stay of proceedings is a ruling by the court in civil and criminal procedure that halts further legal process in a trial or other legal proceeding. The court can subsequently lift the stay and resume proceedings based on events taking place after the stay is ordered.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_Bureau_of_Investigation">Federal Bureau of Investigation</a></td>
      <td>The Federal Bureau of Investigation (FBI) is the domestic intelligence and security service of the United States and its principal federal law enforcement agency. Operating under the jurisdiction of the United States Department of Justice, the FBI is also a member of the U.S. Intelligence Community and reports to both the Attorney General and the Director of National Intelligence.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Philosophical_Investigations">Philosophical Investigations</a></td>
      <td>Philosophical Investigations (German: Philosophische Untersuchungen) is a work by the philosopher Ludwig Wittgenstein, published posthumously in 1953. \nPhilosophical Investigations is divided into two parts, consisting of what Wittgenstein calls, in the preface, Bemerkungen, translated by Anscombe as "remarks".A survey among American university and college teachers ranked the Investigations as the most important book of 20th-century philosophy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Timeline_of_investigations_into_Donald_Trump_and_Russia">Timeline of investigations into Donald Trump and Russia</a></td>
      <td>The timeline of investigations into Donald Trump and Russia is split into the following pages:</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>STERIS CORP      Item 1A Risk Factors       The following are <font color="blue">certain <font color="blue">risk factors</font></font> that <font color="blue">could affect</font> the Company’s     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">risk factors</font>     should be considered in <font color="blue">connection with evaluating</font> the forward-looking     statements  contained in this <font color="blue">Annual Report </font>on Form 10-K because these     <font color="blue">factors could</font> cause the actual results and <font color="blue">financial condition</font> to differ     <font color="blue">materially from</font> those projected in forward-looking statements</td>
    </tr>
    <tr>
      <td>The risks     that are <font color="blue">highlighted</font> below are not the only ones that the Company faces</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and <font color="blue">uncertainties</font> not <font color="blue">presently known by</font> the Company or     that the Company currently deems <font color="blue">immaterial may also affect</font> the Company’s     business</td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">following risks actually</font> occur, the Company’s     business, <font color="blue">financial condition</font>, value, or results of <font color="blue">operations</font> could be     <font color="blue">negatively affected</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">businesses</font> in which the Company competes are <font color="blue">highly competitive</font>, and if     the Company fails to <font color="blue">compete <font color="blue">successfully</font></font>, the Company’s sales and results     of <font color="blue">operations</font> may be <font color="blue">negatively affected</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>operates in a <font color="blue">highly competitive</font> global environment and competes     in each of its <font color="blue">businesses</font> with other <font color="blue">broad line <font color="blue">manufacture</font>rs</font> and many     <font color="blue">smaller <font color="blue">competitors</font> specializing</font> in particular products, primarily on the     basis of brand, product quality, price, warranty, delivery, service and     technical  support</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>anticipates that it <font color="blue">may face increased</font>     <font color="blue">competition</font> in the future as new infection prevention, sterile processing,     <font color="blue">contamination control</font> and <font color="blue">surgical support products</font> and <font color="blue">services enter</font> the     market</td>
    </tr>
    <tr>
      <td>Numerous <font color="blue">organizations</font> are believed to be working with a variety of     <font color="blue">technologies</font> and <font color="blue">sterilizing agents</font></td>
    </tr>
    <tr>
      <td>In addition, a number of companies have     developed <font color="blue">disposable medical instruments</font> and other <font color="blue">devices designed</font> to     address the risk of <font color="blue">decontamination</font></td>
    </tr>
    <tr>
      <td>If the Company’s products, services,     support, <font color="blue">distribution</font> and/or cost structure do not enable it to compete     <font color="blue">successfully</font>, the Company’s sales, results of <font color="blue">operations</font>, or value may be     <font color="blue">negatively affected</font></td>
    </tr>
    <tr>
      <td>The  Company’s  <font color="blue">success depends on</font> its ability to design, <font color="blue">manufacture</font>,     distribute  and  achieve <font color="blue">market acceptance</font> of <font color="blue">new products with higher</font>     <font color="blue">functionality</font> and <font color="blue"><font color="blue">lower cost</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>sells to customers in <font color="blue">industries</font> that are <font color="blue">characterized by</font>     <font color="blue">technological</font> change, <font color="blue">product innovation</font> and <font color="blue">evolving industry standards</font> and     in <font color="blue">which product price</font> is a <font color="blue">key consideration</font> in customers’ purchasing     <font color="blue">decisions</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is engaged in <font color="blue">product development</font> and <font color="blue">improvement</font>     programs  and <font color="blue">must continue</font> to design and <font color="blue">improve innovative products</font>,     <font color="blue">effectively distribute</font> and achieve <font color="blue">market acceptance</font> of those products, and     reduce the costs of producing its products to <font color="blue">compete <font color="blue">successfully</font></font> with its     <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>If the Company’s <font color="blue">competitors</font>’ <font color="blue">product development</font> capabilities     become more <font color="blue">effective than</font> the Company’s, if <font color="blue">competitors</font>’ new or improved     products are <font color="blue">accepted by</font> the market before the Company’s products, or if     <font color="blue">competitors</font> are able to produce <font color="blue">products at</font> a <font color="blue">lower cost</font> and thus offer     products  for sale at a lower price, the Company’s business, financial     condition and results of <font color="blue">operations</font> could be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">consolidation</font> of <font color="blue">health care</font> and <font color="blue">pharmaceutical customers</font> and the     Company’s  <font color="blue">competitors</font>  could  result  in  a loss of customers or more     <font color="blue">significant pricing pressures</font></td>
    </tr>
    <tr>
      <td>Numerous <font color="blue">initiatives</font> and reforms initiated by legislators, regulators and     third-party  payors  to reduce <font color="blue">health care</font> costs have <font color="blue">contributed</font> to a     <font color="blue">consolidation</font> trend among the Company’s customers</td>
    </tr>
    <tr>
      <td>Some of the Company’s     <font color="blue">competitors</font> have been able to <font color="blue">reduce production costs</font> and have lowered the     <font color="blue">purchase prices</font> of their products in an effort to <font color="blue">attract customers</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>has resulted in <font color="blue">greater pricing pressures</font></td>
    </tr>
    <tr>
      <td>Further <font color="blue">consolidation</font> could     result in a loss of customers or more <font color="blue">significant pricing pressures</font></td>
    </tr>
    <tr>
      <td>If the Company’s <font color="blue">cost reduction</font> and <font color="blue"><font color="blue">restructuring</font> efforts</font> are <font color="blue">ineffective</font>,     the Company’s sales and <font color="blue"><font color="blue">profitability</font> could</font> be <font color="blue"><font color="blue">negatively impact</font>ed</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">Company  </font>may  not  be  successful in achieving expected operating     <font color="blue">efficiencies</font> and operating <font color="blue">cost reduction</font>s, and may experience business     <font color="blue">disruption</font>s, associated with <font color="blue">cost reduction</font> and <font color="blue">restructuring</font> <font color="blue">activities</font>,     including the <font color="blue">restructuring</font>                                           9     ______________________________________________________________________    [55]Table of <font color="blue">Contents         </font><font color="blue">activities</font> announced in January 2006 and, in particular, the transfer of the     Erie, Pennsylvania <font color="blue">manufacturing</font> <font color="blue">operations</font> to Mexico</td>
    </tr>
    <tr>
      <td>These <font color="blue">efforts may</font> not     produce the full <font color="blue">efficiency</font> and <font color="blue">cost reduction</font> benefits that the <font color="blue"><font color="blue">Company  </font>   </font>expects</td>
    </tr>
    <tr>
      <td>Additionally, any benefits may be realized later than expected, and     the costs of <font color="blue">implementing</font> these <font color="blue">efforts may</font> be greater than anticipated</td>
    </tr>
    <tr>
      <td>The     Company may undertake additional <font color="blue">cost reduction</font> efforts, <font color="blue">which could</font> result     in  future  charges</td>
    </tr>
    <tr>
      <td>The  Company may be <font color="blue"><font color="blue">adversely</font> affected</font> and could     experience business <font color="blue"><font color="blue">disruption</font>s with</font> its customers and elsewhere if its cost     reduction and <font color="blue"><font color="blue">restructuring</font> efforts</font> prove <font color="blue">ineffective</font></td>
    </tr>
    <tr>
      <td><font color="blue">Decreased </font><font color="blue">availability</font> or <font color="blue">increased costs</font> of <font color="blue">raw materials</font> or <font color="blue">energy costs</font>     <font color="blue">could increase</font> the Company’s costs of producing its products or limit its     ability to produce its products</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>purchases <font color="blue">raw materials</font>, <font color="blue">energy supplies</font>, fabricated components     and <font color="blue">services from</font> a variety of suppliers</td>
    </tr>
    <tr>
      <td>Raw <font color="blue">materials such as stainless</font>     steel and petroleum-based chemicals are considered key <font color="blue">raw materials</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">availability</font> and prices for <font color="blue">raw materials</font> and <font color="blue">energy supplies</font> are subject to     <font color="blue">volatility</font> and are influenced by worldwide economic conditions, speculative     action, world supply and demand balances, inventory levels, <font color="blue">availability</font> of     substitute materials, currency exchange rates, anticipated or perceived     shortages, and other factors</td>
    </tr>
    <tr>
      <td>Where <font color="blue">appropriate</font>, the Company <font color="blue">may employ</font>     contracts with suppliers, both domestically and <font color="blue">internationally</font></td>
    </tr>
    <tr>
      <td>From time     to time, however, the prices and <font color="blue">availability</font> of <font color="blue">raw materials</font> or energy     <font color="blue">supplies fluctuate due</font> to global market demands, <font color="blue">which could</font> impair the     Company’s ability to <font color="blue">procure <font color="blue">necessary</font> materials</font> or produce products or     <font color="blue">could increase</font> the cost of <font color="blue">such materials</font> or products</td>
    </tr>
    <tr>
      <td><font color="blue">Inflationary </font>and     other increases in costs of these <font color="blue">raw materials</font> have occurred in the past     and <font color="blue">may recur from</font> time to time</td>
    </tr>
    <tr>
      <td>In addition, freight costs associated with     shipping and receiving product and sales are <font color="blue">impacted by fluctuations</font> in the     cost of energy</td>
    </tr>
    <tr>
      <td>A reduction in the supply or increase in the cost of oil and     gas  could  <font color="blue">negatively impact</font> the Company’s ability to <font color="blue">manufacture</font> its     products and <font color="blue">could increase</font> the cost of       production</td>
    </tr>
    <tr>
      <td>The Company’s results of <font color="blue">operations</font> may be <font color="blue">harmed by shortages</font>     in supply or increases in prices to the extent <font color="blue">increased costs</font> cannot be     passed on to its customers</td>
    </tr>
    <tr>
      <td>The Company’s <font color="blue">operations</font> and those of its suppliers are subject to hazards     and other risks, any of <font color="blue"><font color="blue">which could</font> interrupt production</font> or <font color="blue">operations</font> or     <font color="blue">otherwise <font color="blue">adversely</font> affect</font> the Company’s performance, results, or value</td>
    </tr>
    <tr>
      <td>The Company’s <font color="blue">operations</font> and those of its suppliers are subject to business     <font color="blue">continuity</font> and other risks, including, but not limited to:            explosions, fires, inclement weather and <font color="blue">disasters</font>;            <font color="blue">mechanical failures</font>;            <font color="blue">unscheduled downtime</font>;            <font color="blue">labor <font color="blue"><font color="blue">difficult</font>ies</font></font>;            an <font color="blue">inability</font> to obtain or maintain any required licenses or permits;            <font color="blue">disruption</font> of <font color="blue">communications</font>;            <font color="blue">inability</font> to hire or retain <font color="blue">key management</font> or employees;            loss of <font color="blue">key executives</font>; and            <font color="blue">disruption</font> of supplies and <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>The occurrence of any of these <font color="blue">problems could</font> cause <font color="blue">disruption</font>, delay, or     otherwise  <font color="blue">adversely</font>  affect  the  <font color="blue">productivity</font> and <font color="blue">profitability</font> of a     <font color="blue">particular <font color="blue">manufacturing</font> facility</font>, or the Company’s <font color="blue">operations</font> as a whole,     during and after the period of these operating <font color="blue"><font color="blue">difficult</font>ies</font></td>
    </tr>
    <tr>
      <td>Certain of     these operating problems may also cause personal injury and loss of life,     severe damage to or <font color="blue">destruction</font> of property and equipment</td>
    </tr>
    <tr>
      <td>Furthermore, the     Company is subject to present and future claims <font color="blue">with respect</font> to workplace     exposure, workers’ compensation and other matters</td>
    </tr>
    <tr>
      <td>Although the <font color="blue"><font color="blue">Company  </font>   </font>maintains property and <font color="blue">casualty insurance</font> of the types and in the amounts     that the Company believes are customary for its <font color="blue">industries</font>, the Company is     not <font color="blue">fully insured against</font> all <font color="blue">potential hazards incident</font> to its business</td>
    </tr>
    <tr>
      <td>10     ______________________________________________________________________    [56]Table of <font color="blue">Contents         </font><font color="blue">The Company </font>conducts its <font color="blue">manufacturing</font>, sales and <font color="blue">distribution</font> <font color="blue">operations</font> on     a <font color="blue">worldwide basis</font> and is subject to the <font color="blue">risks associated with</font> doing business     outside the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has significant international <font color="blue">operations</font>, including <font color="blue">operations</font>     in Europe, Asia and Latin America</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is subject to a number of     risks  that  are inherent in <font color="blue">manufacturing</font>, sales, services, and other     <font color="blue">operations</font> <font color="blue">internationally</font>, including:            <font color="blue">risks associated with</font> foreign currency exchange rate fluctuations;            <font color="blue"><font color="blue">difficult</font>ies</font> in <font color="blue">enforcing <font color="blue">agreements</font></font> and <font color="blue">collecting receivables through</font>     some <font color="blue">foreign legal systems</font>;            <font color="blue">foreign customers may</font> have <font color="blue">longer payment cycles than customers</font> in the     <font color="blue">United States</font>;            tax rates in <font color="blue">certain <font color="blue">foreign countries</font></font> that may exceed those in the     <font color="blue">United States</font> and foreign earnings that may be subject to withholding     <font color="blue">requirements</font>;            tax laws that restrict the Company’s ability to use tax credits, offset     gains, or <font color="blue">repatriate funds</font>;            the imposition of tariffs, <font color="blue">exchange controls</font> or other <font color="blue">trade restrictions</font>     including <font color="blue">transfer pricing restrictions</font> when products produced in one     country are sold to an <font color="blue">affiliated</font> entity in another country;            <font color="blue">general economic</font> and <font color="blue">political conditions</font> in countries where we operate     or where end users of the Company’s <font color="blue">products reside</font>;            <font color="blue"><font color="blue">difficult</font>ies</font> associated with managing a large <font color="blue">organization spread</font>     <font color="blue">throughout various countries</font>;            <font color="blue"><font color="blue">difficult</font>ies</font> in <font color="blue">enforcing <font color="blue">intellectual property</font> rights</font> and weaker     <font color="blue"><font color="blue">intellectual property</font> rights protection</font> in some countries; and            <font color="blue"><font color="blue">difficult</font>ies</font> associated with compliance with a variety of laws and     <font color="blue"><font color="blue">regulations</font> governing international trade</font></td>
    </tr>
    <tr>
      <td>Many <font color="blue">countries also</font> have a <font color="blue">significant degree</font> of political, social, and     <font color="blue">economic uncertainty</font> or unrest that may impede the Company’s ability to     implement and achieve its <font color="blue">international growth objectives</font></td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue">compliance with multiple</font> and <font color="blue">potentially conflicting international laws</font> and     <font color="blue">regulations</font>,  import  and  <font color="blue">export limitations</font> and <font color="blue">exchange controls</font> is     burdensome and expensive</td>
    </tr>
    <tr>
      <td>Changes in <font color="blue">government</font> and other third-party payor <font color="blue">reimbursement</font> levels could     <font color="blue">negatively impact</font> the Company’s sales and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>The Company’s products are sold to <font color="blue">health care</font> providers, hospitals, and     other providers</td>
    </tr>
    <tr>
      <td>Many of these providers are reimbursed for the <font color="blue">health care</font>     services  provided  to  their  patients by third-party payors, such as     <font color="blue">government</font> programs, including Medicare and Medicaid, <font color="blue">private insurance</font>     plans,  and  <font color="blue">managed care programs</font></td>
    </tr>
    <tr>
      <td>Many of these programs set maximum     <font color="blue">reimbursement</font> levels for these <font color="blue">health care</font> services in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>If     the third-party payors deny coverage or reduce their current levels of     <font color="blue">reimbursement</font>  for  health  care services or if the Company’s costs of     <font color="blue">production increase faster than increases</font> in <font color="blue">reimbursement</font> levels, it may     limit the ability of these providers to purchase the Company’s products,     <font color="blue">such as capital equipment</font>, or the Company may be unable to sell its products     on a <font color="blue">profitable basis</font></td>
    </tr>
    <tr>
      <td>Outside the <font color="blue">United States</font>, <font color="blue">reimbursement</font> systems vary significantly by     country</td>
    </tr>
    <tr>
      <td>Many <font color="blue">foreign countries</font> have <font color="blue">government</font>-managed <font color="blue">health care</font> systems     that govern <font color="blue">reimbursement</font> for <font color="blue">health care</font> services</td>
    </tr>
    <tr>
      <td>The ability of hospitals     and other <font color="blue">providers supported by such systems</font> to purchase the Company’s     products is <font color="blue">dependent</font>, in part, <font color="blue">upon public budgetary constraints</font></td>
    </tr>
    <tr>
      <td>If health     <font color="blue">care providers outside</font> the <font color="blue">United States</font> do not obtain <font color="blue">adequate levels</font> of     <font color="blue">reimbursement</font> from third-party payors, international sales of the Company’s     products may decline, <font color="blue">which could</font> <font color="blue">adversely</font> affect the Company’s <font color="blue">total sales</font>     and  could  have  a material adverse effect on our business, financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>11     ______________________________________________________________________    [57]Table of <font color="blue">Contents         </font><font color="blue">The Company </font>is subject to extensive <font color="blue">regulatory</font> <font color="blue">requirements</font> and must receive     and  maintain <font color="blue"><font color="blue">regulatory</font> clearance</font> or approval for <font color="blue">certain products</font> or     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The Company’s <font color="blue">operations</font> are subject to extensive regulation in the United     States and in other countries where the Company does business</td>
    </tr>
    <tr>
      <td><font color="blue">Government     </font><font color="blue">regulation applies</font> to nearly all aspects of testing, <font color="blue">manufacture</font>, safety,     labeling, storage, recordkeeping, reporting, promotion, <font color="blue">distribution</font>, and     the import or export of <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>In general, unless an exemption     applies, a sterilization, <font color="blue">decontamination</font>, or medical device must receive     <font color="blue"><font color="blue">regulatory</font> approval</font> or clearance before it can be marketed or sold</td>
    </tr>
    <tr>
      <td>The     Company can <font color="blue">offer no assurance</font> that a particular device will be approved or     cleared  or  that <font color="blue">such approval</font> or <font color="blue">clearance will</font> be maintained by any     <font color="blue">applicable <font color="blue">regulatory</font> agency</font></td>
    </tr>
    <tr>
      <td>Additionally, the Company may be required to obtain approvals, approval     <font color="blue">supplements</font> or <font color="blue">clearances</font> to <font color="blue">market <font color="blue">modification</font>s</font> to <font color="blue">existing products</font> or     market <font color="blue">existing products</font> for new uses</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">agencies may</font> require     <font color="blue">manufacture</font>rs themselves to make and <font color="blue">document determination</font> of whether or     not a <font color="blue">modification</font> requires an approval, supplement or clearance; however,     the  <font color="blue">regulatory</font> <font color="blue">agencies may</font> review and <font color="blue">disagree with</font> a <font color="blue">manufacture</font>r’s     decision</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has applied for and received many <font color="blue">such approval</font>s in     the past</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>can <font color="blue">offer no assurance</font> that it will be successful in     receiving approvals in the future or that any <font color="blue"><font color="blue">regulatory</font> agency will agree</font>     with its <font color="blue">decisions</font> not to seek approvals, <font color="blue">supplements</font> or <font color="blue">clearances</font> for     particular device <font color="blue">modification</font>s</td>
    </tr>
    <tr>
      <td>The FDA or other <font color="blue">regulatory</font> <font color="blue">agencies may</font>     require approval or <font color="blue">clearances</font> for past or any future <font color="blue">modification</font>s or new     uses for the Company’s <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td>These submissions may require the     submission of <font color="blue">additional clinical</font> or pre-clinical data and may be time     consuming and costly, and may not ultimately be cleared or <font color="blue">approved by</font> the     <font color="blue">regulatory</font>  agencies</td>
    </tr>
    <tr>
      <td><font color="blue">If the Company </font>is unable to obtain any required     approvals, approval <font color="blue">supplements</font> or <font color="blue">clearances</font> for any <font color="blue">modification</font> to a     <font color="blue">previously cleared</font> or approved device, the Company may be required to cease     <font color="blue">manufacturing</font> the modified device or to <font color="blue">recall such modified</font> device until     <font color="blue">appropriate</font> clearance or approval is obtained</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">agencies may</font> also change policies, adopt additional <font color="blue">regulations</font>,     or  revise  existing <font color="blue">regulations</font>, each of <font color="blue"><font color="blue">which could</font> prevent</font> or delay     approval or clearance of devices, or <font color="blue">could impact</font> the Company’s ability to     market a device that was <font color="blue">previously cleared</font> or approved</td>
    </tr>
    <tr>
      <td><font color="blue">If the Company </font>fails to <font color="blue">comply with</font> the <font color="blue">regulatory</font> <font color="blue">requirements</font> of the FDA     or  other  applicable  <font color="blue">regulatory</font> <font color="blue">requirements</font> in the <font color="blue">United States</font> or     elsewhere, the Company may be subject to <font color="blue">administratively</font> or <font color="blue">judicially</font>     imposed  sanctions,  <font color="blue">which could</font> have a material adverse effect on the     Company’s business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>sanctions  include  warning  letters, fines, civil penalties, criminal     penalties, injunctions, <font color="blue">debarment</font>, product seizure or detention, product     recalls and total or <font color="blue">partial suspension</font> of production</td>
    </tr>
    <tr>
      <td>In many of the <font color="blue">foreign countries</font> where the Company markets its products, the     Company is subject to extensive <font color="blue">regulations</font> that are comparable to those of     the FDA The failure to receive, or delays in the receipt of, relevant     <font color="blue">international qualifications could</font> have a material adverse effect on the     Company’s business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Most     </font>notably, the regulation of the Company’s products in Europe <font color="blue">falls primarily</font>     within the <font color="blue">European Economic Area</font></td>
    </tr>
    <tr>
      <td>Only <font color="blue">medical devices</font> that <font color="blue">comply with</font>     certain  conformity <font color="blue">requirements</font> are allowed to be <font color="blue">marketed within</font> the     <font color="blue">European Economic Area</font></td>
    </tr>
    <tr>
      <td>The Company’s products are subject to recalls, even after receiving FDA or     foreign <font color="blue"><font color="blue">regulatory</font> clearance</font> or approval</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is subject to <font color="blue">ongoing medical</font> device reporting <font color="blue">regulations</font> that     require the Company to report <font color="blue">to the FDA </font>or <font color="blue">government</font>al <font color="blue">authorities</font> in     other countries if its products cause or contribute to a death or serious     injury or <font color="blue">malfunction</font> in a way that would be <font color="blue">reasonably likely</font> to contribute     to a death or <font color="blue">serious injury</font> if the <font color="blue">malfunction</font> were to recur</td>
    </tr>
    <tr>
      <td>The FDA and     similar <font color="blue">government</font>al <font color="blue">authorities</font> in other countries have the authority to     require  the recall of the Company’s products in the event of material     <font color="blue">deficiencies</font> or defects in design or <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td>In addition, in light of     a material <font color="blue">deficiency</font> or <font color="blue">design defect</font> or defect in labeling, the <font color="blue"><font color="blue">Company  </font>   </font>may                                           12     ______________________________________________________________________    [58]Table of <font color="blue">Contents         </font><font color="blue">voluntarily elect</font> to <font color="blue">recall one</font> of its products</td>
    </tr>
    <tr>
      <td>A <font color="blue">government</font> mandated or     voluntary  recall  could  occur  as  a  result  of component failures,     <font color="blue">manufacturing</font> errors or <font color="blue">design defect</font>s, including defects in labeling</td>
    </tr>
    <tr>
      <td>Any     <font color="blue">recall would divert managerial</font> and <font color="blue">financial resources</font> and <font color="blue">could harm</font> the     Company’s <font color="blue">reputation with</font> its customers and with <font color="blue">health care</font> professionals     who use and recommend the Company’s products</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>can offer no     assurance that it will not have any <font color="blue">product recalls</font> in the future or that     <font color="blue">such recalls would</font> not have a material adverse effect on the Company’s     business, <font color="blue">financial condition</font>, results of <font color="blue">operations</font>, or value</td>
    </tr>
    <tr>
      <td>The Company’s business and <font color="blue">financial condition</font> could be <font color="blue"><font color="blue">adversely</font> affected</font>     by the <font color="blue"><font color="blue">difficult</font>ies</font> in acquiring and maintaining a <font color="blue"><font color="blue">proprietary</font> intellectual</font>     <font color="blue">ownership position</font></td>
    </tr>
    <tr>
      <td>The Company’s ability to <font color="blue">compete effectively with</font> other <font color="blue">companies depends</font> in     part on its ability to maintain and enforce the Company’s patents and other     <font color="blue">proprietary</font> rights, which are essential to its business</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>relies     on a <font color="blue">combination</font> of patents, <font color="blue">trade secrets</font>, know-how and <font color="blue">confidentiality</font>     <font color="blue">agreements</font> to protect the <font color="blue"><font color="blue">proprietary</font> aspects</font> of its <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">measures afford only</font> limited protection, and <font color="blue">competitors</font> may gain access to     the Company’s <font color="blue">intellectual property</font> and <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>The law of     patents and <font color="blue">trade secrets</font> is <font color="blue">constantly evolving</font> and <font color="blue">often involves complex</font>     legal and factual questions</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>has been and <font color="blue">may continue</font> to be     <font color="blue">necessary</font> to enforce the Company’s <font color="blue">intellectual property</font> rights, to protect     the Company’s <font color="blue">trade secrets</font> and to determine the validity and scope of the     Company’s  <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>can be costly and can divert     management’s <font color="blue">attention from</font> the growth of the business</td>
    </tr>
    <tr>
      <td>Additionally, the     Company may have <font color="blue"><font color="blue">difficult</font>ies</font> maintaining and enforcing its patents and     other  <font color="blue">proprietary</font>  rights  in  some <font color="blue">foreign jurisdictions with weaker</font>     <font color="blue">intellectual property</font> rights</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>can <font color="blue">offer no assurance</font> that its     patents and other <font color="blue">proprietary</font> rights will not be <font color="blue">successfully</font> challenged or     that  others  will  not in<font color="blue">dependent</font>ly develop <font color="blue">substantially equivalent</font>     information  and  <font color="blue">technology</font> or <font color="blue">otherwise gain access</font> to the Company’s     <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>may be <font color="blue"><font color="blue">adversely</font> affected</font> by <font color="blue">product <font color="blue">liability</font></font> claims, legal     actions or other <font color="blue">regulatory</font> or <font color="blue">compliance matters</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>may be subject to a variety of claims, lawsuits, <font color="blue">regulatory</font>     <font color="blue">proceedings</font>,  <font color="blue">investigations</font>,  <font color="blue">debarment</font>  or  other <font color="blue">potential risks</font> or     <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>may be exposed to risks of claims, <font color="blue">proceedings</font>,     <font color="blue">investigations</font> or <font color="blue">litigation</font> by <font color="blue">government</font> agencies or <font color="blue">third parties based</font>     on or relating to <font color="blue">compliance matters</font>, such as product regulation, tax,     <font color="blue">employee welfare</font> or benefit plans, employment discrimination, health and     safety,  <font color="blue">environmental</font>,  antitrust, customs, import/export, <font color="blue">government</font>     contract  compliance, product safety, financial controls or reporting,     <font color="blue">intellectual property</font>, and other matters</td>
    </tr>
    <tr>
      <td>Any such claims, <font color="blue">proceedings</font>,     <font color="blue">investigations</font> or <font color="blue">litigation</font>, regardless of the merits, could result in     substantial costs and <font color="blue">could harm</font> the Company’s business</td>
    </tr>
    <tr>
      <td>Among other risks,     <font color="blue">proceedings</font>, <font color="blue">investigations</font>, <font color="blue">litigation</font> or claims also could require the     Company to:            cease <font color="blue">manufacturing</font> and selling any of the <font color="blue">affected products</font>;            redesign or recall the Company’s products, which may not be possible and     could be costly and time consuming;            restrict or <font color="blue">suspend product sales</font> or other Company <font color="blue">activities</font>; or            pay substantial amounts, revise financial statements, or otherwise     <font color="blue">adversely</font> affect Company performance, results or value</td>
    </tr>
    <tr>
      <td>Additionally,  the Company could be the subject of <font color="blue">regulatory</font> or other     <font color="blue">proceedings</font> that could result in the imposition of <font color="blue">administratively</font> or     <font color="blue">judicially</font>  imposed  sanctions,  such as warning letters, fines, civil     penalties, criminal penalties, loss of tax benefits, injunctions, product     seizure  or detention, <font color="blue">debarment</font>, <font color="blue">product recalls</font> and total or partial     suspension of production</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has been, and is currently, the subject of <font color="blue">product <font color="blue">liability</font></font>     claims and lawsuits relating to its products</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>faces an inherent     business risk of exposure to <font color="blue">product <font color="blue">liability</font></font> claims in the event that one     of the Company’s products is alleged to have resulted in <font color="blue">adverse effects</font></td>
    </tr>
    <tr>
      <td>If     there is a <font color="blue">significant increase</font> in the number, amount or scope of                                           13     ______________________________________________________________________    [59]Table of <font color="blue">Contents         </font>the <font color="blue">product <font color="blue">liability</font></font> claims, the Company’s business could be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>Even  if the Company is successful in <font color="blue">defending against</font> any     <font color="blue">liability</font> claims, such claims <font color="blue">could nevertheless distract management</font>, result     in substantial costs, harm the Company’s reputation, <font color="blue">adversely</font> affect sales     of  the  Company’s products and <font color="blue">otherwise harm</font> the Company’s business,     <font color="blue">financial condition</font>, results of <font color="blue">operations</font>, or value</td>
    </tr>
    <tr>
      <td><font color="blue">Although the Company </font>maintains <font color="blue">product <font color="blue">liability</font></font> and other <font color="blue">insurance with</font>     coverage the Company believes to be adequate, the Company can offer no     assurance that any <font color="blue">product <font color="blue">liability</font></font> or other claims made against it will     not exceed the <font color="blue">coverage limits</font> of the Company’s <font color="blue">insurance policies</font> or that     <font color="blue">such insurance will continue</font> to be <font color="blue">available on terms</font> the Company views as     <font color="blue">commercially reasonable</font> or at all</td>
    </tr>
    <tr>
      <td>Additionally, the Company is subject to     the risk that its <font color="blue">insurers will exclude</font> claim coverage for any reason or     that the <font color="blue">insurers may become insolvent</font></td>
    </tr>
    <tr>
      <td>The results of legal or <font color="blue">regulatory</font> claims, <font color="blue">proceedings</font>, <font color="blue">investigations</font> or     <font color="blue">litigation</font> are <font color="blue">difficult</font> to predict, and the Company <font color="blue">cannot provide</font> any     assurance that <font color="blue">such matters will</font> not be <font color="blue">commenced against</font> it, or that the     Company <font color="blue">will prevail</font> in any claim, proceeding, investigation or <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>An <font color="blue">unfavorable resolution</font> of any legal, <font color="blue">regulatory</font> or compliance matter     <font color="blue">could materially</font> and <font color="blue">adversely</font> affect the Company’s business, results of     <font color="blue">operations</font>, liquidity, <font color="blue">financial condition</font> or value</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>may be unable to <font color="blue">successfully</font> identify, acquire and integrate     <font color="blue">strategic <font color="blue"><font color="blue">acquisition</font> candidates</font></font></td>
    </tr>
    <tr>
      <td>The Company’s ability to <font color="blue">successfully</font> grow through <font color="blue"><font color="blue">acquisition</font>s</font> depends upon     the Company’s       ability  to  identify,  negotiate,  complete  and  integrate  suitable     <font color="blue"><font color="blue">acquisition</font>s</font>, and to obtain any <font color="blue">necessary</font> financing</td>
    </tr>
    <tr>
      <td>The costs of acquiring     other <font color="blue">businesses</font> <font color="blue">could increase</font> if <font color="blue">competition</font> for <font color="blue"><font color="blue">acquisition</font> candidates</font>     increases</td>
    </tr>
    <tr>
      <td>Additionally, the success of any <font color="blue">acquisition</font> is subject to other     risks and <font color="blue">uncertainties</font>, including:            the Company’s ability to realize operating <font color="blue">efficiencies</font>, synergies or     other benefits expected from an <font color="blue">acquisition</font>, and <font color="blue">possible delays</font> in     realizing the benefits of the acquired company or products;            diversion of management’s time and <font color="blue">attention from</font> other business     concerns;            <font color="blue"><font color="blue">difficult</font>ies</font> in retaining key employees, customers or suppliers of the     acquired <font color="blue">businesses</font>;            <font color="blue"><font color="blue">difficult</font>ies</font> in maintaining uniform standards, controls, procedures and     <font color="blue">policies throughout</font> acquired companies;            <font color="blue">adverse effects</font> on existing business <font color="blue">relationships with suppliers</font> or     customers;            the <font color="blue">risks associated with</font> the <font color="blue">assumption</font> of <font color="blue">contingent</font> or undisclosed     <font color="blue">liabilities</font> of <font color="blue">acquisition</font> targets; and            ability to <font color="blue">generate future cash flows</font> or the <font color="blue">availability</font> of financing</td>
    </tr>
    <tr>
      <td>In addition, an <font color="blue">acquisition</font> <font color="blue">could materially</font> impair the Company’s results of     <font color="blue">operations</font>  by  causing  the  <font color="blue">Company  </font>to  incur debt or requiring the     <font color="blue">amortization</font> of <font color="blue">acquisition</font> expenses and acquired assets</td>
    </tr>
  </tbody>
</table>